Cargando…
The Role of Glucocorticoids in the Management of COVID-19
Coronavirus disease 2019 (COVID-19), caused by an infection with the novel coronavirus SARS-CoV-2, has resulted in a global pandemic and poses an emergency to public health systems worldwide. COVID-19 is highly infectious and is characterized by an acute respiratory illness that varies from mild flu...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781662/ https://www.ncbi.nlm.nih.gov/pubmed/33207372 http://dx.doi.org/10.1055/a-1300-2550 |
_version_ | 1783631721857548288 |
---|---|
author | Alexaki, Vasileia Ismini Henneicke, Holger |
author_facet | Alexaki, Vasileia Ismini Henneicke, Holger |
author_sort | Alexaki, Vasileia Ismini |
collection | PubMed |
description | Coronavirus disease 2019 (COVID-19), caused by an infection with the novel coronavirus SARS-CoV-2, has resulted in a global pandemic and poses an emergency to public health systems worldwide. COVID-19 is highly infectious and is characterized by an acute respiratory illness that varies from mild flu-like symptoms to the life-threatening acute respiratory distress syndrome (ARDS). As such, there is an urgent need for the development of new therapeutic strategies, which combat the high mortality in severely ill COVID-19 patients. Glucocorticoids are a frontline treatment for a diverse range of inflammatory diseases. Due to their immunosuppressive functions, the use of glucocorticoids in the treatment of COVID-19 patients was initially regarded with caution. However, recent studies concluded that the initiation of systemic glucocorticoids in patients suffering from severe and critical COVID-19 is associated with lower mortality. Herein we review the anti-inflammatory effects of glucocorticoids and discuss emerging issues in their clinical use in the context of COVID-19. |
format | Online Article Text |
id | pubmed-7781662 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Georg Thieme Verlag KG |
record_format | MEDLINE/PubMed |
spelling | pubmed-77816622021-01-06 The Role of Glucocorticoids in the Management of COVID-19 Alexaki, Vasileia Ismini Henneicke, Holger Horm Metab Res Coronavirus disease 2019 (COVID-19), caused by an infection with the novel coronavirus SARS-CoV-2, has resulted in a global pandemic and poses an emergency to public health systems worldwide. COVID-19 is highly infectious and is characterized by an acute respiratory illness that varies from mild flu-like symptoms to the life-threatening acute respiratory distress syndrome (ARDS). As such, there is an urgent need for the development of new therapeutic strategies, which combat the high mortality in severely ill COVID-19 patients. Glucocorticoids are a frontline treatment for a diverse range of inflammatory diseases. Due to their immunosuppressive functions, the use of glucocorticoids in the treatment of COVID-19 patients was initially regarded with caution. However, recent studies concluded that the initiation of systemic glucocorticoids in patients suffering from severe and critical COVID-19 is associated with lower mortality. Herein we review the anti-inflammatory effects of glucocorticoids and discuss emerging issues in their clinical use in the context of COVID-19. Georg Thieme Verlag KG 2021-01 2020-11-18 /pmc/articles/PMC7781662/ /pubmed/33207372 http://dx.doi.org/10.1055/a-1300-2550 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited. |
spellingShingle | Alexaki, Vasileia Ismini Henneicke, Holger The Role of Glucocorticoids in the Management of COVID-19 |
title | The Role of Glucocorticoids in the Management of COVID-19 |
title_full | The Role of Glucocorticoids in the Management of COVID-19 |
title_fullStr | The Role of Glucocorticoids in the Management of COVID-19 |
title_full_unstemmed | The Role of Glucocorticoids in the Management of COVID-19 |
title_short | The Role of Glucocorticoids in the Management of COVID-19 |
title_sort | role of glucocorticoids in the management of covid-19 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781662/ https://www.ncbi.nlm.nih.gov/pubmed/33207372 http://dx.doi.org/10.1055/a-1300-2550 |
work_keys_str_mv | AT alexakivasileiaismini theroleofglucocorticoidsinthemanagementofcovid19 AT henneickeholger theroleofglucocorticoidsinthemanagementofcovid19 AT alexakivasileiaismini roleofglucocorticoidsinthemanagementofcovid19 AT henneickeholger roleofglucocorticoidsinthemanagementofcovid19 |